

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
31 December 2003 (31.12.2003)

PCT

(10) International Publication Number
WO 2004/000272 A1

(51) International Patent Classification⁷: **A61K 9/08**,
9/10, 31/4174, A61P 11/02

114A, CH-1197 Prangins (CH). **SALVI, Urbano** [IT/CH];
Chemin du Monastier 8A, CH-1260 Nyon (CH).

(21) International Application Number:
PCT/EP2003/006478

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date: **18 June 2003 (18.06.2003)**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM,
PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR,
TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language: **English**

(84) Designated States (*regional*): Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(26) Publication Language: **English**

Published:
— with international search report

(30) Priority Data:
02013693.3 20 June 2002 (20.06.2002) EP

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(71) Applicant (*for all designated States except US*): **NOVARTIS CONSUMER HEALTH S.A. [CH/CH]**; Route de l'Etraz, CH-1260 Nyon (CH).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **RAULT, Isabelle** [FR/FR]; 45, rue du Fontaillon, F-01170 Segny (FR). **MARZANO, Giovanna** [IT/CH]; Toute de Lausanne

WO 2004/000272 A1

(54) Title: NASAL COMPOSITIONS COMPRISING A MUCOPOLYSACCHARIDE AND PROPYLENE GLYCOL

(57) Abstract: The invention relates to pharmaceutical compositions adapted to nasal administration. The nasal formulations of the invention are characterized inter alia by having excellent moisturizing properties and not requiring a preservative.